AB0904 Correlation of rapid3 and promis10 in patients with psoriatic arthritis

Abstract

BackgroundIn addition to clinician assessment and laboratory tests, patient-reported outcomes (PROs) are important for managing and improving the quality of care in patients with psoriatic arthritis (PsA). The RAPID3 was originally developed for use in patients with rheumatoid arthritis, but it may be used in clinical practice to assess disease activity in patients with PsA.1 The PROMIS10 is a general (nondisease-specific) PRO instrument that measures physical, mental, and social health.2 Developed for the general population, PROMIS10 has not yet been specifically validated in PsA.ObjectivesTo evaluate the relationship between RAPID3 and PROMIS10 in patients with PsA.MethodsUS adults with a self-reported diagnosis of PsA were recruited through CreakyJoints (www.CreakyJoints.org), an online patient support community comprising patients with arthritis and arthritis-related diseases and their caregivers. Respondents completed an online survey that was designed to collect data on socio-demographics and clinical symptoms and included the RAPID3 and PROMIS10 to evaluate disease activity and health-related quality of life (HRQoL), respectively. The RAPID3 consists of three patient self-reported scores (0–10): functional impairment, pain, and patient global assessment; total scores≤3.0=near remission, 3.1 to 6.0=low disease severity, 6.1 to 12.0=moderate disease severity, and ≥12.1 = high disease severity. PROMIS10 is a 10-item survey measuring physical and mental domains; individual scores are transformed to T-score distributions normalised to the general population. PROMIS10 individual scores and global physical and mental health T-scores were stratified by RAPID3 disease severity and compared across RAPID3 severity levels using Kruskal-Wallis or ANOVA tests, respectively. Spearman’s correlation coefficient was calculated between RAPID3 total score and the PROMIS10 physical health and mental health T-scores, respectively.ResultsAmong 203 respondents, the mean (SD) age was 51.6 (10.8) years and 172 (84.7%) were female. The mean (SD) cumulative RAPID3 score was 14.7 (5.8) with mean (SD) functional impairment, pain tolerance, and patient’s global estimate scores of 3.3 (1.8), 6.0 (2.3), and 5.4 (2.5), respectively. Patients’ mean (SD) PROMIS10 global physical and mental health T-scores were 36.4 (7.3) and 40.2 (9.3), respectively. The mean individual domain scores and global T-scores worsened with increasing RAPID3 disease severity levels (all p<0.001) (table 1). PROMIS10 physical and mental health T-scores showed a strong (r s=−0.84) and moderate correlation (rs=−0.57) with RAPID3, respectively.Abstract AB0904 – Table 1PROMIS10 Scores and Impact of PsA on Work by RAPID3 Disease Activity in Patients with PsAPROMIS10, Patient-Reported Outcome Management Information System Global Health short form; RAPID3, Routine Assessment of Patient Index Data 3.* Disease severity classified by RAPID3 scores:≤3.0=near remission; 3.1 to 6.0=low severity; 6.1 to 12.0=moderate severity;≥12.1= high severity.ConclusionsRAPID3 and PROMIS10 phys...